{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 39,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a structured layout to compare four distinct market segments (Cutaneous T cell Lymphoma, Alopecia Areata, Vitiligo, Atopic Dermatitis) with specific patient counts and clinical status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/17",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.926,
        "x": 0.037,
        "y": 0.175
      },
      "kind": "callout",
      "text": "Multi-Billion dollar market opportunity for EQ101 in medical dermatology. Large need exists for safe and effective therapies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36ba4f5f-a18b-4e4b-9b86-884e2ae74ead",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "list",
      "text": "Vitiligo: 1.5M+ US Patients; Future Opportunity, Only one FDA approval: JAKi, Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12973cbb-5374-41de-a1d3-8a1c7844480f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.037,
        "y": 0.35
      },
      "kind": "list",
      "text": "Cutaneous T cell Lymphoma: 24,000 adult US Patients; PoC Achieved, Phase 2/3 Ready, Open IND, Unmet need for safe and effective therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "558da637-b332-40ee-928a-016707f50181",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.77,
        "y": 0.35
      },
      "kind": "list",
      "text": "Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity, 3 FDA approved JAKi, Large refractory population in need of safe treatment alternatives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "813c2af4-4d58-45eb-a4e6-38b2028d7c86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.26,
        "y": 0.35
      },
      "kind": "list",
      "text": "Alopecia Areata: 250,000 US moderate-severe Patients; Phase 2 Study ongoing, Only one FDA approval: JAKi, Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "940fa7ec-24b6-4b32-97de-843176300767",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1) Kx Advisors 2) Benigno, Clin Cosmet Investig Dermatol, 2020 3) Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020 4) Chiesa Fuxench ZC, J Invest Dermatol. 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8a1d43d-fcc8-4290-9813-a7655bc6a220",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.715,
        "x": 0.037,
        "y": 0.075
      },
      "kind": "title",
      "text": "EQ101: Valuable Medical Dermatology Franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffe53206-249e-4abe-bc4f-29e15af95549",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "8a8cd690-0173-4620-af29-d74900623b9d",
      "evidence": "The slide contains a list/bullet with several items.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "f55f448b-a29b-44fd-86a7-30db43a0d071",
      "evidence": "The slide segments the total addressable market into four distinct clinical indications with associated patient counts.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 17,
      "beatId": "1b331d6c-cf93-440f-9b58-a2062c2128d5",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck presents market sizing information for EQ101",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}